Every 10-Q that UNITED HEALTH PRODUTS INC (UEEC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow UEEC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UEEC filings page.
United Health Products, Inc. develops and manufactures CelluSTAT, a patented hemostatic gauze, and remains in a pre-revenue stage while pursuing U.S. Class III surgical market approval. For the six months ended June 30, 2026, it reported a net loss of $599,982, improved from $1,854,316 a year earlier, on operating expenses of $432,431.
Total assets were $247,985 and total liabilities $4,690,801, resulting in stockholders’ deficit of $4,442,816. Cash was $24,495 with a working capital deficit of $4,123,570, and the company disclosed substantial doubt about its ability to continue as a going concern.
The company continues to address an FDA Warning Letter tied to its 2018–2019 clinical study, with corrective and preventive actions, a GCP audit, and a plan for NAMSA to act as sponsor of a new IDE study whose data UHP may reference in a future PMA application. Liquidity support includes a convertible note and an Any Market Purchase Agreement with Alumni Capital for up to $4,000,000 in potential equity financing.
United Health Products, Inc. reported another pre-revenue quarter, posting a Q1 2026 net loss of $315,842, a sharp improvement from $1,531,659 a year earlier mainly due to much lower stock-based compensation and reduced R&D and consulting spend.
The company ended the quarter with only $1,029 in cash, a working capital deficit of $4,143,918, total assets of $248,825 and stockholders’ deficit of $4,192,293, and auditors highlight substantial doubt about its ability to continue as a going concern.
UHP remains focused on securing FDA Class III Premarket Approval for its CelluSTAT hemostatic gauze, but is operating under an FDA Warning Letter related to its 2018–2019 clinical study, must complete a GCP audit by late July 2026, and may rely on a prospective corporate partner to serve as sponsor of a new pivotal IDE study. To fund operations it is using highly dilutive instruments including convertible notes and an Any Market Purchase Agreement with Alumni Capital of up to $4,000,000, alongside 40.3 million unvested RSUs and 3.9 million warrants outstanding.
United Health Products (UEEC) filed its Q3 2025 report, showing no revenue as the company focuses on FDA approval for its CelluSTAT surgical hemostatic gauze. The quarter recorded a net loss of $285,594, and the nine-month period showed a net loss of $2,132,440.
Liquidity remains tight: cash stood at $18,376 and working capital was negative $1,963,227. Management stated there is substantial doubt about the company’s ability to continue as a going concern. Financing activity included $420,000 in new convertible notes during the nine months and 800,000 shares sold under the White Lion facility for $63,308; the CSPA commitment period ended on October 1, 2025. Shares outstanding were 258,690,253 as of November 14, 2025.
Regulatory progress remains the key driver. The FDA issued a Warning Letter related to the 2019 clinical study, and in April 2025 the FDA disapproved UHP’s IDE for a 27‑subject supplemental trial pending resolution of that letter. Subsequent to quarter end, UHP received $100,000 via a 60‑day promissory note at 13%, convertible at the holder’s election into notes maturing December 31, 2026.